TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years October 26, 2012
TCL Archive New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial May 30, 2014
TCL Archive In Brief: Pretreatment Critical In Antimetic Therapy, Sallan Says; Aging/Cancer Symposium Planned July 11, 1980
TCL Archive Advocates Call For Metrics And Action Plan In NCI’s Redesign of Cooperative Groups July 8, 2011